Combination therapy versus monotherapy for pulmonary arterial hypertension: A meta-analysis

The Lancet Respiratory Medicine

Volumn 4, Issue 4, 2016, Pages 291-305

  Lajoie, Annie Christine ^a,b   Lauzière, Gabriel ^a,b   Lega, Jean Christophe ^c   Lacasse, Yves ^b   Martin, Sylvie ^a,b   Simard, Serge ^a,b   Bonnet, Sebastien ^a,b   Provencher, Steeve ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ILOPROST; MACITENTAN; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; TREPROSTINIL; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR;

ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADOLESCENT; ADULT; COMBINATION DRUG THERAPY; FEMALE; MALE; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84975763563     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)00027-8     Document Type: Article

References (49)

1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013, 62:D34-D41.
2. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015, 46:903-975.
3. Humbert M, Sitbon O, Simonneau G Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
4. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004, 24:353-359.
5. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369:330-340.
6. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013, 62:D60-D72.
7. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012, 40:874-880.
8. Barst RJ, Gibbs JSR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S78-S84.
9. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009, 30:394-403.
10. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010, 36:549-555.
11. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122:156-163.
12. Fox BD, Shimony A, Langleben D Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol 2011, 108:1177-1182.
13. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006, 28:691-694.
14. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257-1263.
15. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
16. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010, 55:1915-1922.
17. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
18. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012, 126:349-356.
19. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012, 60:1192-1201.
20. Fritz JS, Blair C, Oudiz RJ, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest 2013, 143:315.
21. Cook DJ, Sackett DL, Spitzer WO Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol 1995, 48:167-171.
22. Kramer MS, Feinstein AR Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther 1981, 29:111-123.
23. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
24. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S97-107.
25. Wan X, Wang W, Liu J, Tong T Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014, 14:135.
26. Higgins JPT, Green S Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March, 2011) 2011, The Cochrane Collaboration, (accessed Feb 16, 2016). http://handbook.cochrane.org.
27. Poole C, Greenland S Random-effects meta-analyses are not always conservative. Am J Epidemiol 1999, 150:469-475.
28. Montori VM, Smieja M, Guyatt GH Publication bias: a brief review for clinicians. Mayo Clin Proc 2000, 75:1284-1288.
29. Egger M, Davey Smith G, Schneider M, Minder C Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
30. Moher D, Liberati A, Tetzlaff J, Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62:1006-1012.
31. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011, 30:632-643.
32. Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015, 373:834-844.
33. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010, 31:1124-1131.
34. McLaughlin V, Channick RN, Ghofrani H-A, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015, 46:405-413.
35. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013, 369:809-818.
36. Sitbon O, Channick RC, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015, 373:2522-2533.
37. Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013, 144:952-958.
38. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012, 142:1383-1390.
39. Zhuang Y, Jiang B, Gao H, Zhao W Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res 2014, 37:507-512.
40. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008, 371:2093-2100.
41. Channick RN, Delcroix M, Ghofrani H-A, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail 2015, 3:1-8.
42. Humbert MJC, Galiè N, Hossein AG, et al. Efficacy of riociguat in pretreated versus treatment-naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT-1 study (ATS journals). Am J Respir Crit Care Med 2013, 187:A3534.
43. Rubin LJ, Simonneau G, Hoeper MM, Jansa P, Kusic-Pajic A, Galie N Bosentan improves hemodynamics in patients receiving background sildenafil treatment: results from EARLY a randomized, double-blind, placebo controlled study in patients with mildly symptomatic pulmonary arterial hypertension. Chest 2007, 132:487.
44. Langleben D, Galie N, He J, et al. Baseline characteristics and response to treatment in pretreated versus treatment-naïve patients with pulmonary arterial hypertension (PAH) in the phase III PATENT-1 study. American Thoracic Society 2013, A3532.
45. Channick RN, Delcroix M, Ghofrani H-A, et al. Effect of macitentan on hospitalizations. JACC Heart Fail 2015, 3:1-8.
46. Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest 2013, 144:1521-1529.
47. Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review. Chest 2014, 146:686-708.
48. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010, 122:164-172.
49. Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant 2015, 34:362-368.